| Key WordSubmission Number(s) | |
| 1H MRS M135, M189, W8 | |
| 22q11.2 CNV T12 | |
| 24(S)-hydroxycholesterol M147 | |
| 25-hydroxycholesterol 54.5 | |
| 4-chlorokynurenine (AV-101) T161 | |
| 5-HT1A receptors W280 | |
| 5-ht1b T177 | |
| 5-HT2CR W66 | |
| 5HT5A receptor antagonist W189 | |
| 7T fMRI W16, W280 | |
| ABCD study 4, 35.3, M36, M53, M59, M154, W41, W236 | |
| abstinence W262 | |
| Abuse Liability W220 | |
| acamprosate W272 | |
| accelerated aging T85 | |
| acetylcholine 37.2, 37.4, W4, W15, W264 | |
| Acetyl-L-carnitine LAC 2.3, T142, W89 | |
| Actigraphy M33 | |
| Action-outcome associations 44 | |
| activated microglia T36 | |
| Active Avoidance W212 | |
| Activity-based anorexia W69 | |
| Acute agitation W192 | |
| Acute and Chronic Stress M128, T58, T68, T90, T117 | |
| Acute Stress 23, M125, M133 | |
| Acute Traumatic Stress T7 | |
| Adaptive Behavior M257 | |
| addiction 9, 23, 25.2, 31, 31.4, 52, 56, M230, M255, T48, T49, T54, T241, W241, W262, W271 | |
| addiction circuitry M248 | |
| Addiction phenotypes 31.3, 31.4, 52.4 | |
| adenosine A2A receptor 9.4 | |
| adenosine monophosphate activated protein kinase (AMPK) W242 | |
| Adenosine signaling W217 | |
| adenylyl cyclase W129 | |
| ADHD T108, W55, W114 | |
| Adjunctive therapy M86 | |
| ADL W1 | |
| Adolescence 29.4, 35.2, M43, M49, M57, M61, M62, M138, M242, T42, T53, T84, T242, T278, T280, W194, W246, W249 | |
| Adolescent M46, M231, T72, T128, W41, W59, W93 | |
| Adolescent Alcohol T258, W261 | |
| Adolescent Alcohol Use M58, W232 | |
| Adolescent Anxiety 49.2, M105, T4, W13 | |
| Adolescent Brain Cognitive Development study 59.3, M192, T113 | |
| Adolescent Depression 34.3, 35.2, 35.3, M41, M60, M105, M113, M136, M138, T90, W61 | |
| Adolescent PTSD T83 | |
| Adolescent Stress T277, W259 | |
| Adolescents T108, T266, W50 | |
| adrenal 53.4 | |
| adult T256 | |
| adult anxiety T71 | |
| adult hippocampal neurogenesis W146 | |
| adult neurogenesis W131 | |
| Adult stem cells M206 | |
| adverse childhood experiences (ACE) T93, T102 | |
| Advocacy 15 | |
| affective components of pain 6 | |
| affective disorders 23, 28, M56, T72, T131 | |
| affective instability 32.3 | |
| affective response control M110 | |
| African Americans 13.3, M220 | |
| age T95 | |
| age effects 26, M167 | |
| Ageing 26.3, 46.3, M110, T66, T69, T257 | |
| aggression T249, T251, W38 | |
| aging 50, 57, M4, T68, T227, W5, W98, W120 | |
| Aging and dementia W4 | |
| Agitation M72, T230 | |
| Alcohol 17.1, 40.2, M170, M211, M215, M247, M252, M254, M263, M269, M276, T49, T112, T235, T242, T249, T255, T271, W51, W227, W236 | |
| alcohol relapse treatment M251, W247 | |
| alcohol abuse T240 | |
| Alcohol and substance use disorders 25.5, M255, T116, T159, T238, T239, W240, W276 | |
| Alcohol consumption M240, T240, W233, W265 | |
| Alcohol dependence M63, T61, W226, W238, W265 | |
| alcohol drinking M261, T118, T250 | |
| Alcohol epigenetic marks T261, W233 | |
| alcohol self-administration M253, M260, W247, W251 | |
| Alcohol Sensitivity T250, T251, T257 | |
| alcohol use disorder 10.3, 31.4, 40, M246, M251, M253, T47, T51, T56, T236, T241, T251, T256, T272, W229, W268, W270, W272, W275 | |
| alcohol use disorders T240 | |
| alcohol withdrawal M251 | |
| alcohol withdrawal syndrome T248 | |
| alcohol-induced inflammation W270 | |
| Alcoholism T246, T253 | |
| Alcohol-seeking behavior M243 | |
| allopregnanolone 54, 54.2, 54.4, T31 | |
| allostasis 10.3 | |
| allostatic load 13.1 | |
| allosterism W181 | |
| alpha oscillations T214, T286 | |
| alpha7 nicotinic acetylcholine receptor T195, T280, W213 | |
| alpha-7 nicotinic acetylcholine receptor 53.2, M164 | |
| Alpha-Adrenergic T230 | |
| ALS W148 | |
| alternative medicine T188 | |
| alternative splicing 56.1 | |
| altruism T256 | |
| Alzheimer's M151 | |
| Alzheimers disease W7 | |
| Alzheimer's Disease 42.2, M148, M149, T1, T2, W1, W3, W6, W149, W150, W151 | |
| Ambiguity 52.5 | |
| AMPA T133, W152, W226 | |
| AMPA receptor positive allosteric modulator W74 | |
| AMPA receptors T133, W226 | |
| AMPA TARP gamma8 W152 | |
| Amphetamine M45, T170, W226, W284 | |
| Amygdala 25.2, 32.4, 40.1, 40.2, 44.3, M8, M37, M124, M156, M229, M239, M244, T14, T26, T80, T89, T94, T98, T117, T241, T271, W16, W22, W28, W179 | |
| amygdala-based networks W268 | |
| Amylin M270 | |
| Amyloid 42.2, 42.4 | |
| analgesia 40.1, W230 | |
| Anandamide M100, T75, T243 | |
| androgen W146 | |
| androsterone T183, W11 | |
| anhedonia 23.5, 44.4, 45.1, 45.2, 45.3, 45.4, M60, M111, M135, W119 | |
| Animal Models 24, 42, M43, M85, M139, M141, T272, W146, W182 | |
| Animal Research W212 | |
| ANK3 T165 | |
| Anorexia T13 | |
| anorexia nervosa 27.1, 27.2, T120, W69 | |
| Anterior Cingulate Cortex (ACC) M67, M127 | |
| anterior cingulate gyrus W8 | |
| anthranilic acid M166 | |
| antibiotics W87 | |
| antibody T178, W207 | |
| Anticholinergic medication burden M210 | |
| Antidepressant 20.4, 23.5, 54.3, 58.1, M103, M117, M120, M139, T126, W99 | |
| Antidepressant agents W122 | |
| antidepressant response 20, 45.1, W136 | |
| Antidepressant Trials W140 | |
| Antidepressants M121, M137, T155, W92, W131 | |
| antinflammatory cytokines T158 | |
| antinociception M245 | |
| Antipsychotic 20.4, M76, M117, M161, W201 | |
| Antipsychotic agents M91 | |
| antipsychotic drug M208, W206 | |
| Antipsychotic induced weight gain M162, M196, T148 | |
| Antipsychotic response 20, 21.4 | |
| Antipsychotic Treatment 21.1, M186, W180 | |
| antipsychotic-induced weight gain W196 | |
| Antipsychotic-naïve first-episode schizophrenia 21.3, M166, M186, M207, T216, W163 | |
| Antipsychotics 3.4, 21, M64, M190, T196, W163, W164, W168, W191, W203 | |
| Antisocial Personality Disorder W160 | |
| Anxiety 7, 7.1, 7.3, 8, 32.1, 34.4, 49, 52, 52.5, M6, M16, M18, M30, M46, M74, M96, M246, T6, T33, T84, T128, T241, T258, W27, W30, W87 | |
| Anxiety & PTSD 10, M10, M21, T5, W14, W17, W22 | |
| Anxiety circuitry M25, T19, T86 | |
| Anxiety development 49.3, M27, W13 | |
| anxiety disorders M23, T3, W21 | |
| Anxiolytics W16 | |
| Anxious Depression M100 | |
| apathy T182, T184 | |
| APOE4 allele W3 | |
| appetite W67 | |
| Approach/Avoidance 7.4, M12, M96, W9 | |
| Approach-avoidance T89 | |
| arginine vasopressin T126 | |
| ARIMA model W103 | |
| aripiprazole T208 | |
| Arosual networks T285 | |
| arousal 44.4, W15 | |
| Artifical transcription factors 56 | |
| artificial intelligence M53, T223 | |
| artificial learning M41 | |
| ASD 51.3, M286, W44, W48 | |
| Asperger's Spectrum Disorder W42 | |
| assessment T134 | |
| associative learning M31, M274 | |
| ASSR W285 | |
| Astrocyte 28.5, M235, T201, T206, W217 | |
| astrocytes 28.4, T235, T275, W225 | |
| astroglia 17.3 | |
| Attachment M59 | |
| Attention M249, M281, T84, T109, T252, W35, W199, W267 | |
| Attention Deficit Hyperactivity Disorder T113 | |
| attentional bias 7.1 | |
| attention-deficit/hyperactivity disorder M39 | |
| Attenuated psychosis syndrome W34 | |
| Atypical antipsychotics M196 | |
| auditory cortex M195 | |
| Auditory perception W173, W210 | |
| auditory short-term memory M179 | |
| auditory steady-state response M203 | |
| Autism 16,16.4, 48, 48.2, 50, 51, M55, M83, M280, T111, T113, W42, W56 | |
| Autism & depression 10 | |
| autism spectrum disorder 16.1, 18.5, 22.4, 36, 36.2, 36.4, 50.2, 53, M42, M47, M192, M213, W47, W143 | |
| Autism spectrum disorder and related syndromes 51.2, 51.4, 53.3, M45, M51, T9, T109, W36, W38, W45 | |
| Autoimmune encephalitis M108, T178, W207 | |
| Autonomic nervous system 13.2, 32.1 | |
| Aversive conditioning 32.1 | |
| avoidance W20 | |
| Axonal tract W193 | |
| axons M206 | |
| baclofen T195, W54 | |
| Balb/c mouse T137, W44 | |
| Bariatric Surgery M67 | |
| BAS M36 | |
| Basal forebrain M181 | |
| Basal Ganglia W75, W227 | |
| basolateral amygdala 44, 44.2, M243, M274, W70 | |
| Bay 60-7550 M26 | |
| BDNF M26 | |
| bed nucleus of the stria terminalis T56 | |
| Behavior 24, 31, M83, M104, W88 | |
| behavioral approach M221 | |
| behavioral economics W264 | |
| behavioral inhibition M221 | |
| Behavioral Pharmacology 19.2, T196, T259, T262, T281, W212 | |
| Behavioral Phenotyping 19.2, 31.5, T225 | |
| bench-to-bedside M97 | |
| Benzodiazepine W16 | |
| beta arrestin M201 | |
| beta-adrenergic signalling M281 | |
| bias W181 | |
| biased agonism 41.2, W280 | |
| biased mu agonist 41.5 | |
| biased mu agonists T268, T269 | |
| big data analysis 4 | |
| binge drinking M58, M267, T251 | |
| Binge eating M69, W64 | |
| Binge Eating Disorder M68, M69 | |
| binge-drinking T272 | |
| Binge-eating disorder M69 | |
| binge-eating/purging type M66 | |
| Bioenergetics M139 | |
| Bioinformatics W177 | |
| Biomarker 11.5, 13.3, 14, M118, M144, T29, T164, W74, W129 | |
| biomarkers 2, 21, 45.1, 45.2, M7, T90, T158, W89, W191 | |
| Biomarkers for Risk Assessment 42.5 | |
| biostatistics W273 | |
| Biotypes M115 | |
| Bipolar Depression M84, W80, W123 | |
| Bipolar Disorder M7, M63, M78, M88, M91, M95, M108, M110, M165, M200, M202, T28, T130, T133, T134, T135, T150, T159, T165, T192, T204, T233, W59, W91, W93, W97, W98, W100, W113, W114, W128, W134, W135, W137, W152 | |
| Bipolar I & II disorder M7, T171, W123 | |
| Bipolar I Depression M99, W139 | |
| BIS M36 | |
| Blink T285 | |
| Blood-Brain-Barrier W109 | |
| BNST 40.3, W223 | |
| body dysmorphic disorder W158 | |
| BOLD imaging 7.3, M59, M191 | |
| botulinum toxin M124 | |
| BPSD W1 | |
| Brain 6.4, W10, W52 | |
| Brain age 26.3, T85 | |
| brain aging 42.3, M74 | |
| Brain anatomy 26.2 | |
| Brain Based Markers for Depression T26, W132 | |
| brain connectome 35.3 | |
| Brain development 13.4, 22.1, M27, T94, W228, W284 | |
| brain imaging M16, M269, T256, W40, W263 | |
| BRAIN Initiative 1 | |
| Brain Insulin Resistance 2.3, M5 | |
| Brain Microstructure M191, T221 | |
| brain MRI W8 | |
| brain networks 34.2 | |
| Brain organoids T9, W228 | |
| brain stimulation 58, T163, W138, W258 | |
| Brain Structural Connectivity 13.4, T150, T200, W113, W122 | |
| Brain Structure M27, T7 | |
| Brain training W77 | |
| Brain-enriched exosomes W89 | |
| brexanolone T138 | |
| brown fat activation W214 | |
| bulimia nervosa 27.3 | |
| buprenorphine M272, M277, W269 | |
| Bupropion T148 | |
| calcium imaging 6.3, M201 | |
| CaMKII M225 | |
| Cannabidiol 50.2, M187, T33, T266, T270, W34 | |
| cannabinoid 50.4, T53, W230 | |
| cannabinoids 50.2, T33 | |
| cannabis 50, 50.5, M224, M242, M268, T242, W243, W261, W273 | |
| Cannabis Dependence T237 | |
| cannabis use M57, M216, T188, T262, W232 | |
| cannabis use disorder M221, M268, T276 | |
| canonical correlation analysis W283 | |
| Canonical Correlation Analysis (CCA) M282 | |
| Cardiometabolic Risk 29.3, W5, W137 | |
| Cardiovascular Physiology W93 | |
| care coordination T130 | |
| Cariprazine M99, W143 | |
| catalepsy W230 | |
| catecholamine M275 | |
| CBDV W34 | |
| Celecoxib M84 | |
| Cellular heterogeneity 28.2 | |
| central amygdala W251 | |
| Central autonomic network 57.4 | |
| cerebellum T95 | |
| Cerebrospinal fluid T147, W270 | |
| c-Fos-expressing ensembles M243, T55, T61 | |
| chemogenetics 49.3, M174 | |
| child W59 | |
| Child abuse and neglect T72 | |
| Childhood Adversity T153, W97 | |
| childhood maltreatment W169 | |
| Childhood maltreatment exposure W60 | |
| Childhood Onset Bipolar Disorder W103 | |
| Childhood Psychiatric Symptoms 22.2, M49 | |
| Childhood Stress 13.1, 53.4 | |
| Childhood trauma 43.2, 59.2, M41, T94, W23 | |
| Children M36, M154, M287, T38 | |
| Children and Adolescents M52, M53, M80, T134, T135, W51, W94 | |
| Choice procedure 25.2 | |
| choline 53, 53.2 | |
| Cholinergic 37, M181 | |
| cholinergic system W218 | |
| choroid plexus M150 | |
| chromatin 56.1 | |
| Chromatin modification W221 | |
| chronic mild stress M65, M129 | |
| chronic pain 40.4, 41.4, W33, W257 | |
| chronic pain treatment 6.2 | |
| chronic social defeat T157, W18 | |
| chronic stress 13, 48, 48.1, T140, T172 | |
| Chronic unpredictable mild stress W82 | |
| cingulum T99 | |
| circadian rhythm M33, M88, T65 | |
| circadian rhythms M18, M249, T233 | |
| Circuit M125, W141 | |
| circuit optogenetics 6, 8.4, M243, T86, W144, W259 | |
| Circuit-function T89 | |
| Circuitry-based approach W248 | |
| Classification 27, 27.4, W13 | |
| claustrum W279 | |
| Clinical Development T176 | |
| clinical high risk for psychosis T36 | |
| Clinical High-Risk T219, W174 | |
| Clinical high-risk of psychosis 22.3, 51.4, W188 | |
| Clinical outcome W165 | |
| clinical outcome prediction W140, W188 | |
| Clinical predictors M277 | |
| Clinical psychiatry 47 | |
| clinical psychopharmacology T194 | |
| Clinical Subtypes M136 | |
| Clinical trial 3.4, M94, M100, M134, M157, M160, M261, T76, W80, W96, W203 | |
| Clinical Trial Design M164 | |
| Clinical Trial Methodology W254 | |
| clinical trials M52, T74, W34 | |
| clozapine M190, T194, T211, W189 | |
| Cluster Analysis T171, T199, W254 | |
| Clustering T92 | |
| CNS Clinical Trials T75, T161 | |
| cocaine 17, 28.3, 28.4, 56.2, 56.3, 56.4, M228, M235, M240, M262, M264, M270, T53, T248, T274, W215, W224, W227, W231, W271 | |
| cocaine addiction 25.4, M222, M259, M278, T59, T267, W237, W277 | |
| cocaine reinstatement and taking T260 | |
| cocaine seeking M244, M248, T55 | |
| cocaine self-administration 9.4, 56.1, M239, W264 | |
| cocaine self-administration and reinstatement M217, M244, M258, W242 | |
| cocaine use disorder T204, W222 | |
| coexpression network W209 | |
| Cognition 46.3, 57.1, M6, M95, M99, M143, M145, M147, M167, M181, M193, M281, T37, T69, T162, T198, T204, T211, T234, T286, W5, W67, W77, W146, W166,W220, W279 | |
| cognitive aging T210 | |
| cognitive and affective neuroscience T81, T87 | |
| cognitive behavior therapy M16, M71 | |
| cognitive behavioral therapy W24 | |
| cognitive control M155, T107, T156, T286, W110, W258 | |
| Cognitive Decline T1, T66 | |
| cognitive development T106 | |
| cognitive flexibility 59.4, W59 | |
| cognitive function 2 | |
| Cognitive Functioning M210, T41, W111 | |
| Cognitive impairments M235, T63, W174 | |
| Cognitive Neuroscience 27.2 | |
| cognitive reappraisal 32.3 | |
| cognitive training T239 | |
| Combat PTSD T88 | |
| combat veteran T185 | |
| Comorbidity 57.3, M7, T105, T159 | |
| co-morbidity 28 | |
| Comorbidity depression and CVD 57, W61 | |
| comparative studies T222 | |
| complicated grief M15 | |
| compulsive models of drug use W251 | |
| compulsivity T13, T122 | |
| Computational Methods W187 | |
| computational modeling 7, 7.1, 11, 24, 27.3, 52.3, 58, T81, T284, W194 | |
| computational models of decision-making 31.3, 31.5, M217 | |
| Computational Neuroscience 2 | |
| computational psychiatry 7, 7.2, 7.3, 27, 27.2, 31, 31.3, 38, 52.2, 52.3, 52.4, M134, T15, T48, T135, W24, W86, W133, W210 | |
| Computerized Cognitive Training T239 | |
| Conditioned Place Preference M243, M250, T263 | |
| Confidence W173 | |
| Connectivity 21.3, 34.5, M37, M216, T104, T111 | |
| connectome T284, W116 | |
| connectomics 12.3 | |
| consortium T85 | |
| Conspecific M37 | |
| Context M21 | |
| Contextual cue W215 | |
| contextual fear 8.1 | |
| contingency management T242 | |
| Continous Performance Test M39 | |
| copy number variation W52, W182 | |
| Cortical atrophy 11.4 | |
| cortical circuit function 16.4, M34, M168, M286, T41, T113 | |
| Cortical Development M34, W184 | |
| cortical folding M48 | |
| Cortical GABA M182 | |
| Cortical inhibition W107 | |
| Cortical interneurons W193 | |
| cortical layers T228 | |
| cortical morphology M186 | |
| cortical neurons W222 | |
| Cortical Regions W184 | |
| cortical thickness M48, M58, W178, W287 | |
| corticostriatal T13 | |
| Corticostriatal circuit M31, M89, W222 | |
| Corticostriatal Networks 32.2, M168 | |
| Corticotropin-releasing factor T56 | |
| Corticotropin-releasing factor (CRF) M273 | |
| Corticotropin-Releasing Hormone T22 | |
| Cortisol T47, T90, T102 | |
| Cortisol response to stress T116 | |
| counting Stroop Functional MRI (fMRI) M39 | |
| craving M222, M263, T247, W256 | |
| CREB 56.3, T80 | |
| CRF T274 | |
| CRH T80 | |
| CRISPR 56, W223 | |
| CRISPR/Cas9 18, 18.2, 56.2, M201, W78 | |
| CRISPR/dCas9 56.1, 56.3, 56.4, M204, T52 | |
| critical periods T42 | |
| cross species 49, M33, T48 | |
| cross-species translation 52.2, M96 | |
| CRP M84, T237, W32, W57 | |
| CSF Biomarkers W25 | |
| Cue Reactivity M266, W260, W263 | |
| Cue reinstatement W245 | |
| Cue-Exposure M237 | |
| cue-induced craving M237 | |
| cues M252 | |
| cuprizone short-term exposure M83 | |
| CX3CL1 or fracktalkine 54.2 | |
| cyclic AMP W129 | |
| Cyclooxygenase W139 | |
| Cytochrome P450s 20 | |
| cytokine T162 | |
| cytokines T163, W88, W101 | |
| D1 agonist 46, 46.3 | |
| D1 dopamine receptor 41.5, 46, 46.5, M38, T132 | |
| D1/D2 M193, T57, T259 | |
| D1-PAM 46, 46.3 | |
| D2 dopamine receptor M254, W69 | |
| dACC 29.5 | |
| DART 1 | |
| Dasotraline M68, M69 | |
| Data discovery 4 | |
| Data mining T192 | |
| Data sharing 4 | |
| DBS W155 | |
| de novo mutation W38 | |
| Decision Curve Analysis M115 | |
| Decision Making 44.3, 44.5, 52.2, 52.3, 52.5, M4, T15, T105, W24, W72, W210, W255 | |
| deep brain stimulation 35.5, M101, T184, W124 | |
| deep learning M53, W49 | |
| Default mode network (DMN) M3, T88, T284 | |
| dehydroepiandrosterone T183, W11 | |
| delay discounting M45, M253, T16, W72 | |
| delta opioid receptor M256, W142 | |
| delta9-tetrahydrocannabinol M187, M256, T33 | |
| Delusional disorder W198 | |
| Delusions W198 | |
| Dementia 50.4 | |
| Dementia-related psychosis 42.2 | |
| dendrites 9, M195, M206 | |
| Dendritic spines M204, W95 | |
| dentate gyrus 8.3, M104, M126, M140, M176 | |
| dentin W57 | |
| dependence M252 | |
| Depression 7, 7.2, 7.4, 11.3, 23.5, 26.3, 29.3, 34.4, 57.1, 58.4, 59.5, M43, M46, M62, M63, M75, M81, M85, M90, M102, M116, M119, M121, M127, M130, M139, M142, M174, M232, M288, T6, T19, T24, T25, T64, T125, T133, T145, T151, T153, T175, T283, W82, W86, W87, W88, W90, W99, W101, W104, W115, W117, W136, W138, W219 | |
| Depression Inflammation Cytokine 29, 29.5, 45, M13, M82, W43, W139 | |
| Depression subtypes M115 | |
| depressive symptoms M288 | |
| Depressive-like behavior T172 | |
| Devaluation 44, 44.5 | |
| development 53.4, M206, T97, W57 | |
| Developmental Psychopathology 29, M56, T103 | |
| Developmental trajectory 26, 49, 57, W278 | |
| Dexmedetomidine M72, T230 | |
| diabetes M162 | |
| diagnostic prediction T28 | |
| diet W68 | |
| diffusion MRI T200, W185 | |
| diffusion spectrum imaging W47 | |
| Diffusion Tensor Imaging (DTI) 3.5, 12.3, T103, W35, W59, W122, W167, W183 | |
| diffusion tractography T184, W157 | |
| Diffusion Weighted Imaging 13.4, W170 | |
| Digital 19 | |
| digital assessment 55, W119 | |
| Digital Health Feedback System 55 | |
| Digital phenotyping T65, T223, W200 | |
| dimensions of psychosis T209 | |
| Disability W198 | |
| discontinuation M161 | |
| Discrimination 13.2 | |
| discrimination learning M38 | |
| Disease modeling M151, W78 | |
| Disease prevalence W257 | |
| Disease Progression M151, T221 | |
| Disorders of glutamate M135 | |
| Diverse animal models 36 | |
| diverse populations W205 | |
| DLPFC M67, T117 | |
| DNA double strand breaks M1 | |
| DNA Methylation M151, M204, T217, W98, W233 | |
| DNA sequencing M200 | |
| DNA, whole-genome 18.3, 53 | |
| dnmt T193 | |
| Dopamine 21.4, 23.3, 23.4, 33, 37.4, 40.3, M19, M29, M73, M114, M150, M162, M248, M254, M273, M274, T18, T43, T53, T89, T97, T132, T219, T238, T274, T277, T288, W71, W150, W173, W181, W211, W224, W264 | |
| Dopamine (D2, D3) receptors M162, M217, M218, M237, T50, T208 | |
| dopamine 1 receptor 17.1 | |
| Dopamine 2 Receptor 9.4, 17.1, T236 | |
| Dopamine 3 receptor imaging M218 | |
| dopamine agonists T170 | |
| dopamine receptor heteromer T270 | |
| dopamine release 37.5 | |
| Dopaminergic system 45.4, M260 | |
| Dorsal Hippocampus M250, T59 | |
| dorsal raphe M44, T258 | |
| dorsolateral prefrontal cortex 46, M180 | |
| dorsolateral striatum M239 | |
| Dorsomedial striatum W217 | |
| dose reduction W168 | |
| Doublecortin W131 | |
| DREADDs M126, M264, M267 | |
| drosophila 22.1 | |
| drug abuse M232, M259, M275, T58 | |
| drug addiction 17, 23.2, 31.2, 31.3, W221, W232 | |
| Drug Discovery - new approaches T173 | |
| drug discovery/development M238 | |
| Drug discrimination M227 | |
| Drug metabolism M227 | |
| Drug prime T211 | |
| Drug Relapse W215 | |
| drug repurposing 17.3, 17.4, 23.2, M264, W277 | |
| Drug self-administration 17.1, M40, M231, M245 | |
| drug-drug interaction W244 | |
| Drug-drug-gene interactions M211 | |
| dual viral approach T13 | |
| Duration of Untreated Psychosis M133, M230 | |
| dynamic connectivity M186 | |
| dynamic functional connectivity T30 | |
| Dynorphin W158 | |
| Dyslipidemia M205, M234, T115 | |
| early auditory information processing W19 | |
| early brain development M159 | |
| early diabetes 51.2, T102 | |
| Early identification of risk M64 | |
| early intervention services W94 | |
| Early life adversity W106 | |
| Early Phase Drug Development M32, M41, M44, M92, M104, T98, T224, T234, W172 | |
| early psychosis 17.2 | |
| Early response genes 21.4, T197 | |
| Early Trauma M1 | |
| early-life W53 | |
| early-life adversity T97 | |
| Eating disorders T22, T121 | |
| ecological momentary assessment 27, 27.3, 27.4, T14, T119 | |
| ECT 19.5, M287, W256 | |
| EEG 34.5 | |
| EEG biomarkers M101, T123, T214, T218, W54, W96, W149, W262 | |
| EEG/ERP electrophysiology 51.2, 51.4, 58.1, M40, M179, T40, T41, T195, W45, W104, W110 | |
| Efficacy and safety 51, 51.3, 58, T209, W45, W277, W285 | |
| Effort M215, W80, W201 | |
| effort based decision making task 52.3 | |
| EHMTs 29.5, T170 | |
| electroconvulsive therapy M234 | |
| electroencephalography 58.4, W118, W138 | |
| electronic health record (EHR) 19.4, 22, M258, W99, W191 | |
| electrophysiology 38, M209 | |
| Elevated Plus Maze 35.5, M114, M274, T259, W75 | |
| emergency medicine W212 | |
| emotion 11.2 | |
| Emotion Perception 6.3, M101, M124 | |
| emotion processing 32.4, T203 | |
| emotion regulation T204, T239 | |
| Emotional dysregulation M131 | |
| Emotional Processing 32, T8 | |
| emotional reactivity W111 | |
| Emotional regulation M59 | |
| Emotional stress T99, W94, W261 | |
| Endocannabinoid System M22, M100, M225, W31, W175, W256 | |
| Endocannabinoids W160 | |
| endogenous opioids 37.4, M244, T4, T18, T58, T243, T262, T282, W30 | |
| endophenotype M234 | |
| endotoxin M7, M47 | |
| engram M241 | |
| entorhinal cortex 8, 8.2, 8.4 | |
| Entropy M140, T39 | |
| environmental enrichment M113 | |
| Environmental risk factors 52, T101, T107 | |
| EPHB2 13.4, T93 | |
| epidemiology M55 | |
| Epigenetic W51, W56, W137, W273 | |
| Epigenetic Modification 50.4, T6, T82 | |
| Epigenetics W7, W172 | |
| epigenomics 11.4, 53.3, M75, M204, T57, T111, T145, T234, T271, T279, W6, W98, W109, W221, W276 | |
| epilepsy 53.3, T222 | |
| ERK W152 | |
| escitalopram M259 | |
| Esketamine M23 | |
| Esketamine nasal spray M94, W117 | |
| estradiol T124, T136, W130 | |
| estrogen M97, T166, W121, W234 | |
| estrogen receptor T68 | |
| ethanol 23.3 | |
| ethical issues M240, M254, T277 | |
| ethics 55 | |
| event related potentials 38 | |
| evidence-based approach 51.5, T123 | |
| Evolution T136 | |
| Excitabilty M283 | |
| excitation-inhibition balance T173 | |
| Excitatory Synapses T40 | |
| executive function 16.4, 48.2, M54 | |
| exercise M4, T106 | |
| Exosome 2.3, M150, W68 | |
| expression quantitative trait loci (eQTLs) M11, T71, W27 | |
| extended amygdala W205 | |
| Extended Pedigrees 40 | |
| extended-release depot T131 | |
| externalizing disorders M161 | |
| Extinction T238, W240 | |
| Extinction learning 8, T235 | |
| Extinction recall M239, T5 | |
| Extracellular matrix T5 | |
| Extracellular matrix proteins W245 | |
| extracellular vesicles 13, 13.1, 17.3, M150, T96 | |
| eye-tracking 51.3, T190 | |
| FAAH 31.2, 51 | |
| FAAH inhibitor T4 | |
| face emotion M100, T75 | |
| Facial emotion processing M56 | |
| fallypride binding potential W103, W199, W209 | |
| familial risk of schizophrenia W183 | |
| familiality M207 | |
| fast scan cyclic voltammetry M167 | |
| Fast-acting Antidepressant T18, W71 | |
| Fatty acid amide hydrolase T137, W95, W175 | |
| fatty acids M22 | |
| fear T120 | |
| Fear conditioning T82, W9 | |
| fear extinction 8.3, M8, M10, M12, M19, M50, T241, W28 | |
| Fear learning 8.2, M8, M10, T4, T71, T80, W12 | |
| feeding behavior M10 | |
| female W65 | |
| fentanyl M240, M245, T128, T157, W244, W250 | |
| Fetal M236 | |
| fetal alcohol spectrum disorder 53.4 | |
| Fetal Brain Development T95, T261 | |
| fetal fMRI 43, 43.1, 43.2, M34, T104 | |
| fetal programming 50.5 | |
| First episode psychosis 3, 3.3, 3.5, 22.3, 43, M173, T203 | |
| first episode schizophrenia M197 | |
| first-episode 3.4 | |
| First-Episode Psychosis M203 | |
| FKBP5 W174 | |
| Flanker Task M79, T224 | |
| flavored nicotine W110 | |
| fluoxetine T278 | |
| fMRI 34.2, M16, M31, M67, M78, M124, M224, M269, M286, T118, T128, T256, W40, W68, W81, W246 | |
| fMRI negative affective stimuli 32.4, 43, M20, M165, W91 | |
| fMRI resting state 59.4, T26, W132 | |
| fMRI/imaging genetics M282 | |
| FNDC5/irisin 26, W40 | |
| follow-up M200 | |
| food intake W68 | |
| Food restriction T118 | |
| Fragile X syndrome 16.4, M40, M54, W69, M278, W54 | |
| Frontoparietal W170 | |
| Frontoparietal Network W149, W279 | |
| frontostriatal circuitry T88 | |
| frontotemporal dementia T200 | |
| Frustrative Non-Reward W156 | |
| FTO M80 | |
| functional and structural MRI T145 | |
| functional and structural neuroimaging T37 | |
| Functional capacity 35.4 | |
| functional connectivity M185, T207, W2 | |
| functional genomics 27.1, M156, M283, W29, W269 | |
| functional imaging W52 | |
| functional impairments 34.5 | |
| functional magnetic resonance imaging M172 | |
| Functional MRI (fMRI) T144, W240 | |
| Functional neuroimaging 7, 7.1, 7.2, 25.3, 25.4, 29.4, 32, 32.3, 34.4, 35.3, 40.4, 49.2, 51.5, M11, M12, M80, M168, M222, M226, M266, T3, T5, T30, T63, T107, T159, T208, T249, T250, T252, W24, W84, W199, W202, W209, W236, W258, W261, W263, W267 | |
| Functional outcomes 27.3, 49, T121, W103, W182, W284 | |
| Functional Selectivity M197 | |
| functional variants W280 | |
| G protein and chemokine signaling 6.2, W129 | |
| GABA 6 | |
| GABA neuron M189, M219, M257, T9, T31, T43, T127, T138, W79, W107 | |
| GABA-A receptors T228 | |
| GABAB T138, W276 | |
| GABAergic boutons W250 | |
| GABAergic circuitry T228 | |
| GABAergic interneuron migration 1.5 | |
| GABAergic interneurons M38 | |
| Gabapentin W228 | |
| GAD M251 | |
| gamma oscillation T193 | |
| gaze fixation M171, M203 | |
| gender W48 | |
| Gender differences W220 | |
| gene co-expression W42 | |
| Gene co-expression networks W182 | |
| Gene editing M279 | |
| gene expression 36 | |
| Gene priming M228, M279, T12, T246, T259, W101, W182 | |
| gene regulation W221 | |
| gene transcription 18.3, M34 | |
| generalized anxiety disorder M1 | |
| genetic animal model W24 | |
| Genetic association study T259 | |
| Genetic Disorder M237 | |
| genetic mouse models W40 | |
| genetic risk factor 6.2 | |
| genetics 26.2, 47, M200 | |
| Genetics of depression 14, 21, M145 | |
| Genetics of temperament W112, W118 | |
| Genome-wide association studies 18.3, 56 | |
| genome-wide association study W118, W272 | |
| genomics 1.2, 12, M176, T192 | |
| geriatric depression 11, M175 | |
| glia 42.5 | |
| gliosis 28, W131 | |
| globus pallidus 30 | |
| GLP-1 M172 | |
| GLP-1 receptor M270, T49 | |
| GLT-1 T49, T248 | |
| glucocorticoid W225 | |
| Glucocorticoid antagonists T47 | |
| glucocorticoid receptor M215 | |
| Glucocorticoids M79, W85 | |
| glucose metabolism W44 | |
| glutamate 2.3, T248 | |
| glutamate GABA 12.4, 21.4, M129, M189, M264, M273, T25, T142, T216, T253, T267, T277, W89, W162 | |
| Glutamate homeostasis T137, W184 | |
| glutamate transporter (EAAT3) M219, W218 | |
| glutathione 46.5 | |
| glycine transporter 1 29.4 | |
| Glycolysis W44 | |
| goal-directed behaviors T143 | |
| Gonadal Hormones 44.2 | |
| GPCR W72, W255 | |
| GPCRs M193, W129 | |
| GR chaperone M193 | |
| graph theory W85 | |
| Graph-based Analysis 27.1 | |
| gray matter volumes M165 | |
| GrimAge acceleration T72, T153 | |
| GSK3 11.4 | |
| Gut Microbiome M171 | |
| gut microbiota T27, T231, T272, W36, W87 | |
| Gut-brain axis W140 | |
| GWAS T231 | |
| GWAS LOCI T240 | |
| habenula 53 | |
| habit M46, W30 | |
| habit formation 27.2 | |
| Habitual decision-making W71 | |
| Hallucinations M239, T13 | |
| hallucinogens W173 | |
| Health M201, M226 | |
| Health Disparities 13.3 | |
| health-related quality of life 30 | |
| Healthy controls T127 | |
| heart rate variability 13.2, W169 | |
| heritability 57.2, 57.4, T8 | |
| Heritability of depression W55 | |
| heroin M245, T57, W112, W215 | |
| heroin self-administration 17, M272, W234 | |
| Herpesvirus 17.3, 23.2, 28.3, 28.5, T245, W225, W249 | |
| high fat diet M90 | |
| High potency THC W61 | |
| High-Risk T266, W243 | |
| hippcampus T143 | |
| hippocampal CA3 W146 | |
| Hippocampal Function M256 | |
| Hippocampal subfields M49 | |
| Hippocampal-prefrontal W164 | |
| hippocampus M21, M31, T39 | |
| Histone acetylation 8.1, 8.2, 8.3, M79, M176, T94, T98, T145, W95, W106, W150 | |
| histone deacetylase T279 | |
| Histone methylation T57 | |
| homer W23 | |
| Hormones M278 | |
| hospitalization risk W53 | |
| HPA 3.3, W198 | |
| HPA axis 53, T126 | |
| human brain imaging 13.1, M79, T168 | |
| human connectome W121 | |
| human connectome project (HCP) 34, 34.4 | |
| Human Genetics 34.2 | |
| human imaging 36.2, 51.2, M106, M128, T34, T131, T166, T244, W42, W112 | |
| Human Laboratory Study 6 | |
| human microglia T33, T51 | |
| Human Neuroimaging W10 | |
| human post-mortem brain 12, 23.5, 25.4, 26, 27.4, 34.3, 35.2, 51, 58, M27, M223, T84, T182, T256, T283, W154 | |
| humanized D1 receptor knock-in mice W241 | |
| humans 46.3 | |
| Huntington's Disease T52 | |
| Hybrid PET/MR M146, M147, W156 | |
| hydroxynorketamine T177, T208, T269 | |
| hyperalgesia M111, T137 | |
| hypersexual disorder M24 | |
| Hypertension M71 | |
| Hypothalamic development 57.4, W5 | |
| hypothalamus 57.2 | |
| hypothermia M222 | |
| IgLONs W230 | |
| IL-1b M152 | |
| Imaging W197 | |
| immediate early gene M181 | |
| immediately early gene W44 | |
| Immune 8.3 | |
| Immune Biomarkers M148, M279 | |
| immune cells 13, 29.4, M95, T237 | |
| Immune responses T190 | |
| immune system M241 | |
| implicit priming T186 | |
| impulsive sensation seeking W263 | |
| impulsivity M78, M246, T247, W160 | |
| in vivo calcium imaging M73, T16, T122, T234, T249, T251, T253, W72, W73 | |
| In vivo Imaging 8.1, M25, T39, T86, T263 | |
| incentive salience 21.4, T32 | |
| incubation of cocaine craving M284, W73, W268 | |
| Incubation of drug craving M225, M257 | |
| Independent Component Analysis 17.4, T45, W277 | |
| individual differences M218 | |
| individual variability M284, W58 | |
| Induced pluripotent stem cells (iPSCs) M190 | |
| Infancy 18, 18.2, 18.5, 46.5, M51, W78, W100 | |
| infant 51.2 | |
| infant sleep pattern W48, W49, W58 | |
| infection 22.2 | |
| inferior frontal gyrus M90 | |
| inflammation M84, M119, T159 | |
| Inflammatory Markers 14, M6, M81, M108, T37, T142, T162, T201, W57, W92, W101, W125 | |
| Inhibition M92 | |
| Inhibitory control T98 | |
| inhibitory neurons M269, W235, W267 | |
| innate immune response W282 | |
| innate immunity M82 | |
| Insight 54.5 | |
| insomnia M155 | |
| Insula T5 | |
| insular cortex M37, W132, W166, W261 | |
| insulin M120, T14, T50, W67, W179 | |
| Insulin resistance M196, M270 | |
| Insulin-like growth factor 1 57.1, M127, M162, M166, T211, W89 | |
| Integrative Health W145 | |
| integrin 9, T26, W132 | |
| intergenerational transmission of stress 13.2 | |
| interleaved TMS/fMRI 53.4 | |
| Interleukin 1 receptor W22 | |
| Interleukin 1beta T186 | |
| Interleukin-6 T186 | |
| Interleukins T157 | |
| Intermittent Explosive Disorder W139 | |
| internet T123 | |
| interneuron W134 | |
| interoception W227 | |
| interpeduncular T121, W27 | |
| interpersonal psychoterapy M271 | |
| intervention W8 | |
| Intracellular Signaling W200 | |
| Intraparietal Sulcus T173 | |
| intravenous administration M283 | |
| intravenous drug self-administration W252 | |
| intrinsic functional connectivity M236, W216, W234 | |
| intrinsic motivation T283 | |
| ion channels M222, T225, W202 | |
| iPSC 23, T173 | |
| irritability M88 | |
| Irritability/Aggression M80, M89, M96, M287 | |
| item response theory M146, T123 | |
| ITI-007 W176 | |
| IV- Ketamine W123 | |
| journal function M87, M141, M142 | |
| kalirin W282 | |
| kappa agonist M195 | |
| Kappa Opioid Receptor M205, M226 | |
| Kappa Opioid Receptor Antagonist M260, T115, T277 | |
| kappa opioid receptors 45.3 | |
| ketamine 34.5, M121, M137 | |
| kinases 12.4, 34, M60, M81, M111, M120, M121, M137, M174, M232, T21, T125, T164, W33, W83, W95, W117, W127, W133 | |
| Kinome array W147 | |
| Kynurenic acid W177 | |
| Kynurenine W197, W213 | |
| kynurenine pathway M109, M135, T198, W139 | |
| L-655,708 W213, W285 | |
| lactate T154 | |
| Large Scale Networks M189 | |
| Laser Capture T187 | |
| Late Life Depression 49.3 | |
| Late-life Depression T158 | |
| Latent class analysis W116 | |
| Lateral Habenula W235 | |
| Lateral hypothalamus M121, M133, T21, T24 | |
| lateral orbitofrontal cortex T43, W144 | |
| L-DOPA 44.2, W135 | |
| leading eigenvector dynamics analysis M240 | |
| learning and memory W158 | |
| lemborexant T3, T39 | |
| leptin M211 | |
| Lifetime stress M166 | |
| Light Therapy M6, W112 | |
| lipids 12.3 | |
| liquid chromatography/mass spectrometry W92 | |
| Lithium M234 | |
| Lithium response M120, T165, W135 | |
| liver-brain axis W128 | |
| lobules W270 | |
| local field potentials T95 | |
| local protein synthesis M170, T16 | |
| Locus coeruelus T268, W197 | |
| Locus coeruleus (LC) M72, T1 | |
| Long Access self-administration M129 | |
| Long Term Potentiation 28.4 | |
| Long-acting injectable antipsychotics M101 | |
| longitudinal imaging 3.4, W180 | |
| Longitudinal MRI M57 | |
| long-term potentiation 3, W47 | |
| long-term results T218 | |
| long-term safety T202 | |
| Long-term treatment M69, M161, W203, W204 | |
| low-dose 5, T128, T205 | |
| Lower Urinary Tract Symptoms (LUTS) W7 | |
| LSD W21 | |
| LSD microdosing 59, 59.3 | |
| L-thp M112 | |
| Lumateperone M160, W123 | |
| lungs T196 | |
| lurasidone T264 | |
| Lymphatics W172 | |
| M1 and M4 Muscarinic Receptors 48.3 | |
| M5 muscarinic receptor 37.5 | |
| Macaque Monkey 44.4, W159 | |
| Machine learning 26.3, 31, M145, M179, W184 | |
| machine learning classification 11.2, 19.2, 19.5, 26, 27.1, 31.3, 38, 58.1, M170, M184, T16, T29, T63, T72, T223, W119 | |
| Machine learning clustering M253, T28, W163, W233 | |
| Magnetic Resonance Imaging 11.5, M136 | |
| magnetic resonance spectroscopy 6.4, M24, M41, M74, M242 | |
| maintenance treatment 59.4 | |
| major depression 57.3, W168 | |
| Major Depressive Disorder (MDD) 34.2, 34.5, 42.3, 45.1, 57, 59.4, M103, M106, M107, M108, M131, M134, T30, T126, T144, T156, T167, W77, W84, W96, W102, W108, W109, W125, W130, W245, W265 | |
| Major depressive episode 34, 45.2, 57.4, M86, M94, M109, T29, T148, T149, T168, W106, W119, W131, W147 | |
| maladaptive feeding M103 | |
| maltreatment W64 | |
| marijuana T94 | |
| Marijuana Policy M224, T237, W219, W220 | |
| marmoset T266 | |
| maternal behavior T178 | |
| Maternal Depression W269 | |
| maternal immune activation M74 | |
| MATRICS Consensus Cognition Battery (MCCB) 19.3, M170, T10, T101 | |
| MATRICS Consensus Cognitive Battery M66 | |
| Matrix Metalloproteinase-9 (MMP-9) W174 | |
| MDMA 39 | |
| MDMR 39, 59, 59.2, 59.3, W14 | |
| Medial frontal cortex M283 | |
| Medial Orbitofrontal Cortex M194, T137 | |
| Medial Prefrontal cortex 44.2, 44.3, W135 | |
| Medial septum M8, M75, T42, T61, T91, T255, W65, W95, W144, W282 | |
| mediation analyses T2 | |
| Medication Assisted Treatment M268 | |
| Medication Development T248 | |
| medications 5, M245, T51 | |
| mediodorsal thalamus W273 | |
| Medium spiny neurons M194, T61 | |
| MEF2C 56.4 | |
| melanocortin 16.4 | |
| Melatonin W65 | |
| memantine W153 | |
| memory 8, 8.1, 8.4, 17.2, M119, M159, T69, W151 | |
| Memory and Learning 57.3, M224 | |
| Memory Encoding and Retrieval 10.2, M140, T44, T67 | |
| memory reconsolidation M5, M250, W260 | |
| Meninges 10.2, W29, W231 | |
| Menopause 48.3, M3, M5 | |
| Mental Disorders 13.1, 53.4 | |
| Mentoring W76 | |
| mesolimbic reward circuitry 28.2, 30, T168 | |
| meta-analysis 45, M45 | |
| Metabolic Syndrome M52, M190, T236, W14 | |
| metabolism T120 | |
| metabolomics W275 | |
| Metabolomics signature M109, T272, W19 | |
| metabotropic glutamate receptor 5 (mglu5) T267 | |
| metformin M258 | |
| methadone M64, W242 | |
| Methamphetamine M230, M236, M272 | |
| methylphenidate 25.2, M223, T52, T219, W262 | |
| mGlu2/3 receptor M39 | |
| mGluR5 negative allosteric modulator T267 | |
| mGluR5 receptors M276 | |
| mice M217, M278, W219 | |
| microbiome T112, T190 | |
| Microbiota-gut-brain axis T11, W266 | |
| Microdialysis W37, W140 | |
| Microdosing with psychedelics T280 | |
| microglia 28.2, T141, W76 | |
| microglia and neurons 28.3, 48.1, 48.2, 54.5, T22, T139, T163, W36 | |
| Microglia priming 6, M82 | |
| microglial activation 48, T265 | |
| microscopy 48.3 | |
| midbrain 28.5 | |
| migraine 40.3 | |
| mild cognitive impairment due to AD W142 | |
| Mild Traumatic Brain Injury 42.4, M149, W2 | |
| Mindfulness Meditation T181, T185, W35 | |
| mineralocorticoid receptor T78, T88, W84 | |
| miR-30a M79 | |
| Mismatch Negativity W172 | |
| Mitochondria T195, T226 | |
| Mitochondrial DNA M180, T35, T275, W206 | |
| Mitochondrial function 13, 13.1, M32, T143 | |
| mitochondrial genetics M6 | |
| Mobile technology T35 | |
| Model systems T65 | |
| model-free and model-based learning 22 | |
| modeling 31.2, 44 | |
| Molecular genetics 58.4, M106, M265, M280, T244 | |
| Molecular imaging 36 | |
| Molecular profiling 42 | |
| monetary incentive delay task T14 | |
| Monetary reward M223 | |
| monoamine oxidase B M102, M105, W236 | |
| monocytes W62 | |
| Mood 13.1, 48.1, 53.4 | |
| mood and anxiety disorders M112, M138, M287, W67 | |
| mood disorder 34 | |
| Mood disorder subtypes M135, T162, T173 | |
| mood disorders 7.3, 32.2, 35, M33, M87 | |
| Mood stabilizers 2, 35.4, 48, M76, M107, T166, W94 | |
| MOR M91 | |
| morphine T66, W117 | |
| Motivated maternal approach behaviors 40.2, 41.2, 56.3, M227, T265, T268, T275, W216 | |
| motivation W60 | |
| Motor abnormalities 52.3, M221, M253, T18, T19, T132, W73, W202 | |
| motor activity W165 | |
| motor function M33 | |
| motor learning T223 | |
| Mouse and monkey models W208, W288 | |
| mouse behavior 36.4 | |
| Mouse model T140, W288 | |
| mPFC 8.2 | |
| MR imaging W238 | |
| MR spectroscopy T92 | |
| MRI 12.3 | |
| mRNA M48, M53, M154, M216, T95, T181, W287 | |
| MRS T193 | |
| MT2 RECEPTOR W162 | |
| mTOR W153 | |
| mTORC1 T69 | |
| multidimensional predictors of susceptibility T147 | |
| Multi-electrode arrays T142 | |
| multimodal data M219 | |
| multimodal Imaging W240 | |
| Multi-modal imaging M145 | |
| multimodal neuoimaging M191 | |
| Multimodal Neuroimaging W163 | |
| Multimodality neuroimaging T7, T29 | |
| Multi-omics 29, 35, 35.5 | |
| Multiplex families M151 | |
| multi-ROI M200 | |
| multivariate approaches M263 | |
| mu-opioid receptor agonist M53, W49 | |
| mu-opioid receptors T268 | |
| Muscarinic T268, T269, W248 | |
| muscarinic M1 M181 | |
| MVPA T132 | |
| myelin 25.3, M10 | |
| Myelination T112 | |
| Myotonic dystrophy M51, W237 | |
| naloxone T182 | |
| Naltrexone T265 | |
| Nasal delivery T51, T60, W272 | |
| Natural Compound W192 | |
| natural language processing (NLP) W6 | |
| Neanderthal-derived Admixture M209 | |
| Negative Affect M283 | |
| negative allosteric modulator M129, M278, T115 | |
| negative emotion 9.4, W159 | |
| neonatal M163, M183, M208, T41, T225, W166, W179 | |
| neonatal abstinence syndrome T99, T104 | |
| Network-Analysis M272 | |
| Neural circuit and animal behavior M13, M255, W13, W29 | |
| neural circuits 36.4, M265, W248 | |
| neural cirucitry M152, M198 | |
| neural complexity 42 | |
| Neural connectivity W104 | |
| neural flexibility 16 | |
| Neural Modelling M113, T30 | |
| neural oscillations 52.4 | |
| Neural Predictors W82 | |
| Neuregulin 34.3 | |
| neuregulin-3 53.2 | |
| neuroactive steroid T254 | |
| neuroanatomy T138, T183, W11, W287 | |
| Neurocircuits M48 | |
| Neurocognition 1.5, M192, T108, T156 | |
| Neurocognitive assessment M197 | |
| Neurocognitive Function M155, W1 | |
| Neurocognitive functioning 32.2 | |
| neurodegeneration W1, W41, W167 | |
| Neurodegenerative Disease M118, T227, W156 | |
| neurodevelopment M145, W193 | |
| neurodevelopmental and behavioral deficits T11, T103, T105, W49, W185 | |
| Neurodevelopmental disorder M55, W143 | |
| neurodevelopmental disorders 16, 22, 22.1, T92, W40, W56 | |
| Neuroeconomics 52, W34 | |
| neuroendocrinology 13.1, 53.4, T48 | |
| Neuroepigenetic editing T23 | |
| Neurogenesis T2 | |
| neurogenetics M104, W107 | |
| neurogranin M48 | |
| neuroimaging 26.3, T98, T158 | |
| Neuroimaging Analysis 11, 11.3, 14, 21, 50.5, M107, T64, W135, W141, W178 | |
| neuroimaging biomarkers M134, T287 | |
| Neuroimmune T141, T144 | |
| neuroimmune mechanisms 45.4, M175, W10, W185 | |
| Neuroimmunology 19.3, T69, W36 | |
| neuroinflamation 48.3, T11 | |
| neuroinflammation 43, T265 | |
| neuro-inflammation 2.3, 29.3, 43.1, 48, 48.1, 54.3, 54.5, M83, T36, T139, W7, W185 | |
| Neurokinin T206, W61 | |
| neuromedin U M116 | |
| Neuromelanin-sensitive MRI W253 | |
| Neurometrics T1 | |
| Neuromodulation T287 | |
| neuronal tracing T167, W75, W141 | |
| Neuron-glial interactions W253 | |
| Neuropathic pain 28.2, 41.4, W153 | |
| neuropeptides W25 | |
| neuropharmacology M116, W253 | |
| Neuropharmocology T281 | |
| neurophysiology 10.2 | |
| neuroprotection 42.5, W77 | |
| Neuropsychiatric Disorders W287 | |
| Neuropsychiatric Disorders [Schizophrenia, Parkinson's Disease, Major Depressive Disorder] 5, 19.3, 24, M279, T224 | |
| Neuropsychiatric symptoms (NPS) 46, M83, T193, T195, T221, T231, W177 | |
| neuropsychology W207 | |
| Neuropsyhiatric Disorders M57 | |
| neuroregeneration 10.5 | |
| neurosteroid 54, 54.4, 57.2, T31, W287 | |
| neurosteroids 54.3, T183, W11 | |
| Neurostimulation 54.2, W276 | |
| neurosurgery for psychiatric disorders M158 | |
| neuroticism W157 | |
| neurotransmission M29 | |
| neurotransmitter co-release T44 | |
| Neurotransmitter release T24 | |
| neurotrophic 46.3 | |
| neurotrophin signalling W107 | |
| Neurotrophins W172 | |
| Neurovascular T111 | |
| New intervention targets W109 | |
| next generation sequencing 27 | |
| nicotine 6.2 | |
| nicotine addiction M229, M281, T252, W246 | |
| nicotine dependence T254, T278, W218 | |
| Nicotine exposure W258 | |
| Nicotine Metabolism T107, T264 | |
| nicotine vapor T60 | |
| nicotine withdrawal T264 | |
| nicotinic acetylcholine receptors T254, W267 | |
| nicotinic receptor T109, W246 | |
| nitric oxide T110 | |
| NLRP3 M264, M271 | |
| NMDA T139 | |
| NMDA glutamate receptors 51.5, W148 | |
| NMDA glycine-site receptor M235, T161 | |
| NMDA Receptor T161, W285 | |
| NMDAR M143, M144, M147, M171, T178, T226 | |
| Nociceptin/orphanin FQ M247, W117 | |
| NODDI W12 | |
| Non-addictive 21.3, M191 | |
| non-coding DNA T176 | |
| Non-human primate 7.4, 18.5, T178, T273 | |
| nonhuman primate model W66 | |
| Nonhuman Primate Models 49.3 | |
| Nonhuman Primates T103 | |
| Non-Suicidal Self-Injurious Behavior M37, M182, W252 | |
| noradrenaline 25.3 | |
| Noradrenergic System W25 | |
| norepinephrine T255 | |
| novel antidepressant M65, T1, T59, W15 | |
| novel methods M93 | |
| Novel Targets W191 | |
| Novel Tool W148, W253 | |
| novelty seeking 1.5 | |
| Nucleus Accumbens 56.2, T132, T288, W278 | |
| nucleus accumbens (NAA) 28.4, 37.4, 56.1, 56.3, 56.4, M13, M257, T57, T115, W9, W245, W259 | |
| nucleus accumbens core W231 | |
| Nucleus Accumbens Shell 17.3, M262, M267, T245, W69 | |
| obesity 42.3, 57.1, M5, M127, M166, M185, M265, T14, T58, T245, T263, W67, W68, W70, W214 | |
| Observational learning M152 | |
| Obsessive Compulsive Disorder M50 | |
| Obsessive-Compulsive and Related Disorders M68, M157, T188, W157 | |
| obsessive-compulsive disorder (OCD) M155 | |
| obsessive-compulsive spectrum disorders (OCDS) M154, M156, M158, T33, T35, T187, W21, W155 | |
| OCD phenotypes W156 | |
| olanzapine T105 | |
| oligodendrocytes W192 | |
| Omega-3 Fatty Acid M51 | |
| Omega-3 fatty acids W113, W125 | |
| ondansetron T150, T197, W114, W284 | |
| Onfant M63 | |
| Open Label Trials 6.4 | |
| opiate addiction W203 | |
| opiates 40 | |
| opioid T273 | |
| Opioid abuse 6.3, W153 | |
| Opioid addiction T50, W244, W253 | |
| Opioid agonist treatment 17.4, 31.5, 41, M232, T275, W245, W248, W254, W257 | |
| Opioid antagonist treatment 41, W256 | |
| opioid dependence 41, W244 | |
| opioid epidemic- novel approaches M236 | |
| opioid overdose 1.3 | |
| Opioid system 41.2 | |
| opioid use disorder M265, T21 | |
| opioid withdrawal 19.5, 41.5, M250, M277, T273, W159, W241, W256, W266, W269 | |
| opioids M236 | |
| Oprk1 gene expression 1, 1.2, 1.5, W228, W241 | |
| optical biosensors M260 | |
| optogenetics 1, W15 | |
| orbitofrontal 19.4, M4, M25, T39, W70, W141 | |
| orbitofrontal cortex (OFC) 44.4 | |
| orexin 44.5, T45, T79, T114 | |
| orexin receptor antagonist M86, W223 | |
| Organoids W64 | |
| oscillations 18.5 | |
| Oscillatory Activity W149 | |
| Outreach 46.5 | |
| ovarian hormones 15 | |
| ovarian steroids M97, T166 | |
| oxidative stress W121 | |
| oxysterols T45, W159 | |
| oxytocin 54, 54.5, T243, T288 | |
| oxytocin and addiction W16 | |
| Oxytocin receptor gene methylation M71, W247, W252 | |
| P2X7 M42 | |
| P50 T139, W96, W197 | |
| pain 6.4, 32, 32.1, 40, 40.1, 40.2, 54.4, M65, M164, T114, T115, T258 | |
| pain analgesia 6.3, W11 | |
| Pain therapeutics 40.3, 41.4 | |
| pair bond T176 | |
| Palatable food T288 | |
| PANSS Inconsistencies T55 | |
| paraventricular nucleus of the hypothalamus W176 | |
| paraventricular nucleus of the thalamus 57.2, T22 | |
| Parent - child dyads T56, W9 | |
| Parkinson's disease M50 | |
| Parvalbumin fast-spiking GABAergic interneurons 46.5, T184 | |
| parvalbumin interneuron T42 | |
| Parvalbumin neurons W195 | |
| Pathophysiology M25, M171, M182, T91 | |
| Patient Reported Outcomes 27, 27.4 | |
| Pavlovian conditioning T130 | |
| PCLO M284, W264 | |
| pediatric M157, W186 | |
| Pediatric Bipolar Disorder M23, W43 | |
| pediatric PTSD T143 | |
| performance enhancement T4, W8 | |
| periaqueductal grey (PAG) 58.3 | |
| Perinatal 40.2 | |
| perinatal anxiety M157 | |
| perinatal depression T27 | |
| Perinatal stress T27 | |
| Perineuronal nets W269 | |
| peripheral biomarker T91 | |
| Personalized dosing M109 | |
| PET 58 | |
| PET imaging 42.5, M217, M218, T25, T47, T166, T185, W4, W10, W66, W121, W141, W175, W211, W214, W226 | |
| PET Imaging Study M174 | |
| PFC T116 | |
| Pharmacodynamics M4, W22 | |
| Pharmacoepidemiology M215, W192 | |
| Pharmacogenetic Response W180 | |
| pharmacogenetics 47, W136 | |
| pharmacogenomics 20.4, M117, T151, W128, W272 | |
| Pharmacokinetics M187, T147 | |
| Pharmacology M117, W192 | |
| pharmacotherapy M275, T281 | |
| Pharmacovigilance M251, M276, W143 | |
| Phase II clinical trial W142 | |
| Phenotypes M146, W17 | |
| Phenotyping T171 | |
| phosphatase 31, T122 | |
| Phosphodiesterase-2 M259 | |
| Phosphodiesterase-4 (PDE4) M26 | |
| photometry W151 | |
| photopharmacology W227 | |
| pimavanserin W186 | |
| PKA/PKG M163, M208 | |
| Placebo Response M26 | |
| placebo-controlled trial 7.2 | |
| placenta 50.2 | |
| Plasticity 53.3, T101, T155 | |
| Polydrug Use 26.2 | |
| Polygenetic Risk Score M268 | |
| polygenic risk score 18.4 | |
| polygenic risk scores M288, T78, W42, W196, W265 | |
| polygenic scores M29, T199, T240 | |
| polymorphism W209 | |
| Polypharmacy T236 | |
| Positive Affect M76 | |
| positive allosteric modulators T110 | |
| Positron emission tomography 37.5, M143, M144, M238, T226 | |
| positron emission tomography (PET) 42.4 | |
| positron emission tomography imaging M29, M275, T36, T219, T238, T247, T276, W62, W97, W127, W160 | |
| Post Traumatic Stress Disorder M22 | |
| Postmortem Brain Tissue 11.3, M15, T8, T70 | |
| postmortem human brain 12.1, M180, M199, M202, M204, W147, W177, W194, W237 | |
| postpartum T192 | |
| postpartum depression M114, M288 | |
| post-transcriptional processing 22.2, M97, T127, T138, W79 | |
| Posttraumatic Stress Disorder T149, W31, W195 | |
| poverty T85 | |
| PPI T106 | |
| Precision Medicine for Mood Disorders W197 | |
| Precision Medicne neuropsychiatric diseases 7.3 | |
| precision psychiatry M117 | |
| Preclinical T28 | |
| Preclinical Alzheimer's Disease 59.5, W284 | |
| Preclinical and clinical studies W6 | |
| Pre-clinical screening 25 | |
| precuneus T176 | |
| prediabetes W103 | |
| Prediction M64 | |
| Prediction error 19 | |
| Predictive Models 27.4 | |
| predictor of treatment response T135 | |
| prefrontal circuit W83, W91, W128, W191 | |
| Prefrontal cortex 37.4, M13, M43, M235, T109, T112, T141, W85, W183 | |
| prefrontal-amygdala-connectivity M205 | |
| pregnancy 49.2, M89 | |
| Pregnenolone 22.2, 43.1, 54.4, T155 | |
| prelimbic cortex 54 | |
| premenstrual dysphoric disorder M262 | |
| premorbid and current IQ T31 | |
| prenatal 50, T199 | |
| Prenatal Drug Exposure 50.5 | |
| Prenatal exposure M59 | |
| prenatal programming W51 | |
| Prenatal stress 43.2, 57.3, M3, T102, W37 | |
| prenatal stress-immune model T96 | |
| Prescription Opioids 43 | |
| Presynaptic mRNA W248 | |
| preterm birth T67 | |
| progesterone M92 | |
| proinflammatory cytokines M97, W234 | |
| Pro-inflammatory cytokines W216 | |
| propranolol T36 | |
| proprotein convertase subtilisin/kexin 9 M281, W260 | |
| protein complexes W270 | |
| protein degradation 9.4 | |
| protein synthesis 1.3 | |
| Proteomics 16.1 | |
| proton magnetic resonance spectroscopy 42.2, W237 | |
| pruning M85, T216 | |
| Psilocybin M173 | |
| Psychedelic medicine 39, 59, 59.4, W102, W111 | |
| Psychedelics 59, M112 | |
| Psychiatric Comorbidity M226, W76, W102, W111, W120 | |
| psychiatric disorders W50 | |
| Psychiatric Education 2 | |
| psychiatric genetics 47 | |
| psychiatric genomics 11.5 | |
| psychobehavioral intervention 18, 18.2 | |
| psychological distress 35.4 | |
| psychomotor speed W120 | |
| Psychoneuroimmunology W101 | |
| Psychopathology W207 | |
| Psychopharmacology Treatment Guidelines W165 | |
| psychophysics T194 | |
| psychophysiology M179 | |
| Psychosis 21, 37, M187, M192, M200, M209, M280, M288, T219, T227, W23, W31, W167, W169, W175, W185, W200, W202 | |
| psychosis continuum M193, T131 | |
| psychosocial stress T37, W210 | |
| Psychotherapy T119 | |
| psychotic 39, T76, W14, W134 | |
| psychotic depression M130 | |
| Psychotic Disorders W178 | |
| psychotic-like experiences 32.4, M183 | |
| Psychotropic drug load T38 | |
| Psychotropic Medications M76 | |
| PTSD 39, T167 | |
| Puberty 8, 8.3, 11.2, 11.4, 13.3, 59, 59.2, M11, M19, M20, M24, M26, M247, T7, T76, T78, T81, T87, W10, W19, W23, W25, W31, W32, W33 | |
| pulmonary W53 | |
| punishment T264, W70 | |
| Pyramidal Cell W81 | |
| Pyramidal neurons M180 | |
| Quantitative EEG 46 | |
| R-(-)-ketamine M149, W145 | |
| Racism 13.2 | |
| raclopride 13.3 | |
| radiation T208 | |
| randomized clinical trial W7 | |
| randomized controlled trial M64 | |
| Randomized-Controlled Trial 50.2 | |
| rapamycin W124 | |
| Rapid Information Processing T125 | |
| Rapid-acting Antidepressant M39 | |
| Rare genetic variants M93, T29, T125 | |
| rat W38 | |
| Rat models T274 | |
| rats T91 | |
| Rbfox1 W216 | |
| RCT W195 | |
| RDoC 29 | |
| Readmission risk 32.3, 34.2, T284, W283 | |
| real-time fMRI neurofeedback M209 | |
| REAP M263 | |
| recent onset psychosis M76 | |
| receptor binding W181 | |
| Receptor Occupancy W230 | |
| reconsolidation intervention M218 | |
| recruitment W29 | |
| Redox modulation T74 | |
| Reelin W187 | |
| reinforcement W100 | |
| Reinforcement learning M237, T18, T279 | |
| Reinforcement Learning Modelling 31.2, 32.1, W133 | |
| Reinstatement 52.4, W215 | |
| relapse W216 | |
| relapse biomarkers 9, 17, M230, T267, W218, W263 | |
| relapse circuits 31.5, W86, W268 | |
| relapse prevention M230 | |
| relapse-prevention 3 | |
| REM sleep M103 | |
| remifentanil W213 | |
| remission W234 | |
| repetitive behavior W136 | |
| repetitive transcranial magnetic stimulation M45 | |
| repetitive transcranial magnetic stimulation (rTMS) 40.4, W80 | |
| replacement therapy M131, T149, T167, W90 | |
| Replication 9 | |
| Research domain criteria (RDoC) M78 | |
| Resilience 11.3, 32, M49, M207 | |
| Resilience Induction T142, W169 | |
| Resting and task fMRI T62 | |
| Resting state M249, T285 | |
| Resting state functional connectivity 34, M42, M275, W285 | |
| Resting state intrinsic connectivity 29.3, 51.5, M46, M89, M154, M172, M186, M221, T62, T76, T83, T144, T233, T247, T287, W58, W84, W90, W94, W166, W188, W246, W283 | |
| Resting state networks T250 | |
| Resting-state fMRI M183, W158 | |
| resting-state functional MRI 21.3, 27.1, M3, M113, M142, T76, T175, T187, W268 | |
| restricting type M85 | |
| Resveratrol M66 | |
| Retest Reliability W6 | |
| Retina T287 | |
| Rett Syndrome T181 | |
| reversal learning W145 | |
| rewad drive M21, M31 | |
| reward 23.5, M61, M125, T279, W9, W81, W275 | |
| reward and aversion 28 | |
| reward circuitry T260, W75 | |
| reward devaluation 45.4 | |
| Reward functioning T118 | |
| reward learning 29.4, 45.3, T214, W235 | |
| reward network M80, M284, T43 | |
| Reward processing 45, M285, T54 | |
| Reward self-administration 32 | |
| Reward Sensitivity T54 | |
| Reward-based decision-making 32.2, W73 | |
| Rhesus T170, W217 | |
| RhoA T79, T82, W244 | |
| Risk and Resilience 44.3, M280 | |
| risk assessment 42, M246 | |
| Risk factors W56 | |
| risk-taking M78, W278 | |
| Risky decision-making M61 | |
| RNA Sequencing T260, W70 | |
| RNAseq 49.3, M51, W52 | |
| RNA-seq 12.1 | |
| RNA-sequencing M141, W241 | |
| Rodent models M77, M133, M176, T265, T271 | |
| Rodents W12, W173 | |
| rsfMRI 23.2, T52, W64 | |
| Safety 58.1 | |
| SAGE-217 T147 | |
| SAGE-718 T127, W79 | |
| salience network M143, M144 | |
| Salience processing of infant cues M172 | |
| salvinorin A W60 | |
| samidorphan M226 | |
| schizoaffective disorder W170 | |
| Schizophrenia 3.4, 3.5, 18.3, 18.4, 21.1, 22.4, 33, 37.2, 53, 53.2, M34, M108, M159, M160, M161, M165,M168, M172, M173, M174, M175, M184, M190, M191, M192, M195, M200, M202, M203, M205, M206, M210, M286, T28, T41, T192, T198, T201, T204, T206, T207, T210, T217, T218, W78, W163, W164, W165, W166, W168, W174, W179, W180, W186, W191, W193, W194, W195, W196, W203, W205, W208, W211 | |
| schizophrenia genetics T133 | |
| schizophrenia negative symptoms M176 | |
| Schizophrenia novel treatment W176 | |
| Schizophrenia- Novel Treatment 37.5, M72, M164, T40, T215, T226, W34, W189, W204 | |
| schizophrenia spectrum disorder W201 | |
| schizophrenia subgroups M64 | |
| Schizophrenia subtypes T199 | |
| Schizophrenia; ; Technology M185, T215, W187 | |
| Schizophrenia; Technology T223 | |
| Schizophrenia-like Behavior W170 | |
| Science education M170, T43 | |
| SCN2A 15 | |
| screen time W78 | |
| screening T38 | |
| Seasonality W273 | |
| Secondary Sex Ratio T233 | |
| selective mTORC1 activation 19.4 | |
| Selective Serotonin Reuptake Inhibitors (SSRIs) M93 | |
| self-administration T27, T52, T264, W81 | |
| self-control T274 | |
| Self-medication with psychedelics T15 | |
| self-perception W76 | |
| Seltorexant T119 | |
| Senescence Associated Secretory Phenotype M86 | |
| sensorimotor 42.3 | |
| sensory gating M47 | |
| sensory processing 22.4 | |
| sequencing 51.4, M198 | |
| Serine Racemase 18.3, 53 | |
| Serotonin W193 | |
| serotonin 1a receptor M44, T27, T59, T86, T97, T177, T186, T258, W121, W280 | |
| Serotonin 1b receptor M104, T116, T153 | |
| Serotonin 5-HT2A Receptor W73 | |
| Serotonin 5-HT2C Receptor 41.5, 59.3, M163, M201 | |
| Serotonin Transporter M238 | |
| Sertraline 42.4, W81, W127 | |
| serum levels M11, T31 | |
| sex M187 | |
| sex differences 13.1, 43, 53.4, 57, M50, M224, T6, T62, T96, T210, W13, W88 | |
| Sex hormones 57.3, M3, M81, M141, M227, M228, M244, M252, M256, M267, M272, T11, T56, T59, T112, T140, T172, T193, T235, W36, W82, W255, W259 | |
| sex steroids T6 | |
| Sexual Dimorphism W19 | |
| SHANK3 gene mutation T217, T257, W28 | |
| Shank3-deficient mice 36.4 | |
| signal transduction T209, W56 | |
| signaling 6.2 | |
| sign-tracking W181 | |
| silent synapses 31.2 | |
| single cell omics W231 | |
| Single-cell 1 | |
| Single-cell RNA sequencing 1.2 | |
| Skin conductance responses 18.5, M8, M199, M202, T79, W221 | |
| sleep M50 | |
| sleep deprivation 10, 10.2, 10.3, 19.4, 22, 22.1, M128, T44, T106, W208 | |
| sleep disorders 12.3, W214 | |
| sleep disturbance 10.5 | |
| sleep homeostasis 22.2, M213, M277, T108, W5 | |
| Sleep inconsistency M249 | |
| sleep spindles M249 | |
| slow waves 22, 22.3, 22.4 | |
| Smoking 22.3 | |
| Smoking Cessation W219 | |
| sociability M220, M261, T60, W260 | |
| Social and behavioral deficits M38 | |
| social anxiety 36 | |
| social anxiety disorder T75 | |
| social attachment M22 | |
| social behavior 25.2, 51.3, M114, M213, T87, T243, W37, W199, W282 | |
| social behaviors T190 | |
| Social brain W144 | |
| social cognition 25, M102, T119 | |
| Social Competence M66, M183, T87, T197, T203, W199 | |
| Social defeat stress 25.4 | |
| Social Discrimination M82, M116, W61 | |
| social dominance 13, T117 | |
| Social Factors and Functioning W144 | |
| Social Functioning 25 | |
| social interaction W200 | |
| Social Interactions 25.3 | |
| social isolation stress 25.4, W18 | |
| social media M65, M285 | |
| Social Media Use T74 | |
| social motivation T74, T90, W200 | |
| social neuroscience T209 | |
| Social Processing 25.5 | |
| Social rejection M286 | |
| Social responsiveness M102 | |
| Social reward M42 | |
| Social support 59.3, M102, M105 | |
| Sodium nitroprusside 25.5 | |
| Somatosensory processing T196 | |
| Somatostatin T32 | |
| splicing M182 | |
| SSRI W229 | |
| staging M23 | |
| STAR*D W154 | |
| Startle T151 | |
| State dependence W17 | |
| statins 27.3, 58.3 | |
| Stem Cells W3 | |
| Stimulants 18.4, T111 | |
| Stress T15, T247 | |
| Stress and anxiety behavior T141, T168, W88 | |
| stress and anxiety disorders W20 | |
| Stress and Depression 8.2 | |
| Stress Coping W112 | |
| stress in adolescence T117 | |
| Stress models M228 | |
| Stress resilience M75, M77 | |
| stress-immune dysregulation T140, W109 | |
| stress-induced reinstatement 43 | |
| striatum T235 | |
| Structural and Functional Connectivity 37, 37.2, 44, 44.2, M54, M62, M254, W38, W71 | |
| structural covariance analyses M67 | |
| structural MRI T85 | |
| structural neuroimaging 35.3, M127, M197, T12, T23, T118, W49, W106, W115 | |
| Subjective Cognitive Impairment M138, W164 | |
| subjective effects 42.5 | |
| Substance abuse T250, T262 | |
| Substance abuse disorders T234, W235 | |
| Substance P 17.2, M271 | |
| substance use disorder 25, M116 | |
| substance use disorders 14, T279 | |
| Suicidal behavior 28, M232, T171 | |
| suicidal ideation T116, T282, W130 | |
| Suicidality T93 | |
| suicide 12, 12.1, 35.2, 35.4, M89, M107, M113, M280, T64, T171, W43, W85, W115, W147 | |
| Suicide attempt 12.4 | |
| Suicide prediction M184, T282, W50 | |
| suicide prevention 35, M107 | |
| Suicide risk factors M52 | |
| superolateral medial forebrain bundle 35, T93, T114, W50 | |
| suprachiasmatic nucleus W124, W155 | |
| Surgery M18 | |
| symptoms T66 | |
| Synapse T25, W167 | |
| synapse growth-pruning T141 | |
| synaptic aberrations T22 | |
| synaptic dysfunction T133 | |
| Synaptic Function W195 | |
| synaptic organizers W75 | |
| synaptic plasticity 16, 59.5, M152, W218 | |
| Synaptic protein imaging 17 | |
| synaptic protein interaction networks T276 | |
| Synaptic Ras-GTPase activation protein M152 | |
| Synaptogenesis M38 | |
| Synaptotagmin 1 50.4 | |
| Synchronized Transcranial Magnetic Stimulation (sTMS) W238 | |
| Synchrony M125 | |
| systemic inflammation T110 | |
| systems neuroscience 11.5 | |
| systems pharmacology W15 | |
| TAAR 1 T246 | |
| TAAR1 W204 | |
| tardive dyskinesia 33, T215 | |
| Target engagement T202, T205 | |
| Targeted interventions M30, M164 | |
| Task vs Rest 35 | |
| task-based functional connectivity M165 | |
| tau T63 | |
| TBI 42.4 | |
| tDCS M158 | |
| Technology W258 | |
| technology-assisted treatment T207 | |
| telemetry 3.3, W2 | |
| Telomeres 19.3, T10 | |
| temperament W98 | |
| temporal integration 49 | |
| temporal optimization M179 | |
| testosterone 58.3 | |
| thalamo-cortical connectivity W72 | |
| Thalamo-cortical Interactions T61 | |
| Thalamus 22.3, M168 | |
| Thalamus - Reticular nucleus M24, W282 | |
| THC 22.4 | |
| theory of mind M231, T270, W249 | |
| Theory of mind and reward functional networks T203 | |
| Therapeutics M42 | |
| theta burst transcranial magnetic stimulation 10.5 | |
| thorough QTc study M30, T70 | |
| threat context T3, W29 | |
| Threat of Shock T123 | |
| timing W17 | |
| TMS M194 | |
| TMS EEG 58.3, M30, T175, W74, W104 | |
| Tobacco M20 | |
| Tobacco Smoking W51 | |
| tobacco-specific nitrosamine M241, T244 | |
| Tolerability M220 | |
| Toll-like receptor T147 | |
| Toll-Like receptors (TLRs) 48.3 | |
| top-down control 54.2, T10 | |
| Topiramate T109 | |
| topoisomerase M266 | |
| touchscreen M1 | |
| Toxoplasma gondii M285 | |
| Trace amines-associated receptor 1 T198 | |
| transcranial direct current stimulation M20 | |
| transcranial magnetic stimulation M21 | |
| transcription 40, 44.5, M115, T64, T70 | |
| transcription imputation M75, W266 | |
| Transcriptome T222 | |
| Transcriptomics M13, M148, M180, W206, W229 | |
| transcutaneous auricular vagus nerve stimulation (taVNS) 11.5, M141, M199, T67, T80 | |
| Transdiagnostic 57.4 | |
| trans-diagnostic 32.4, M282, T105 | |
| transgenerational transmission T122 | |
| transgenic mice T261 | |
| Transition to Broad Psychosis Spectrum Psychopathology M150, M171, W149 | |
| Translation M207 | |
| translation initiation 16 | |
| Translational 16.1 | |
| translational biomarker development 19, 50 | |
| translational models M115, W45, W74 | |
| Translational Neuroscience W34 | |
| Translational research 24, 40.4, 42, M85, T48, T103, T170, W4, W106, W260 | |
| trauma T124 | |
| trauma and stress disorders T81 | |
| Trauma exposure M32 | |
| Traumatic Brain Injury 11.3, T8, T47, W32, W62 | |
| Traumatic Memories T183 | |
| Traumatic stress M24 | |
| Treatement resistant depression W12 | |
| Treatment M93, T124 | |
| Treatment Mechanisms 12, M15 | |
| treatment outcome prediction T26, W84, W132 | |
| treatment refractory M209, W99 | |
| Treatment Resistant Depression W189 | |
| treatment resistant schizophrenia 35.5, M60, M120, M126, M137, T136, T161, T164 | |
| Treatment response M190, W162 | |
| Treatment-refractory depression 21.1 | |
| Treatment-related changes in resting state functional connectivity M87 | |
| Treatment-resistance T83 | |
| Treatment-resistant depression M84 | |
| treatment-resistant schizophrenia M118, W83, W122, W124, W133 | |
| Treatment-Response M163, T194, T211 | |
| Tricarboxylic acid 21.3, W118, W136 | |
| trichotillomania T143 | |
| tryptophan T34, W154 | |
| TSPO W213 | |
| TSPO and [11C]PBR-28 PET T237 | |
| tuberous sclerosis complex M241 | |
| twins W45 | |
| Two-photon imaging W108 | |
| two-photon microscopy 1.3 | |
| ubiquitination M198, T139 | |
| ultra high-risk youth M200 | |
| ultrasonic vocalization T41 | |
| UNC0642 treatment T91 | |
| Uncinate Fasciculus T15 | |
| V1b antagonist T99 | |
| valbenazine T126 | |
| valence T202, T205 | |
| vaping T19, T86 | |
| Vapor M229, W232 | |
| Varenicline W250 | |
| vasopressin W267 | |
| Vasopressin 1a receptor antagonist 57.2 | |
| ventral hippocampus M146, W17 | |
| Ventral Striatum 56.2, M25, M77, T154 | |
| Ventral Tegmental Area (VTA) 17.1, 29.5, M105, W202 | |
| verbal learning 23.3, M73, M129, M257, M260, M274, T58, W224 | |
| verubecestat W169 | |
| Virtual Reality M250, T114, W25 | |
| Visual T3 | |
| visual information processing 51.5 | |
| Visual Processing 51 | |
| Visual stimulation 51.3, M286, T203 | |
| visuospatial working memory T163, T177 | |
| VMAT2 T228, W184 | |
| vmPFC T202 | |
| vole T55 | |
| Voltage-Gated Calcium Channel T288 | |
| vortioxetine W288 | |
| Voxel-Based Morphometry (VBM) M103 | |
| VTA M36 | |
| Vulnerability W250 | |
| Vulnerability traits M49, M92 | |
| weather M284 | |
| White Matter M130 | |
| white matter fractional anistropy 3.5, W53, W116, W167, W170 | |
| white matter integrity W55 | |
| Whole exome sequencing T99, T102 | |
| Whole Genome M200, T34 | |
| Whole Genome Sequencing T271, W52, W108 | |
| Whole-Brain Rodent Imaging T131 | |
| Withdrawal W20 | |
| women T248, T252, W243 | |
| Women's Health W23 | |
| Women's Mental Health 13.1, 53.4 | |
| Working Memory M205, T23, T146 | |
| Worry M231, T63, T286, W209 | |
| xCT M30 | |
| young adults T248 | |
| youth M74 | |
| Zaleplon M96, M282, T238 | |
| zebrafish W212 | |
| zinc 36.2 | |
| α5-GABAA receptor negative allosteric modulator W271 | |
| α-synuclein T154, T158 |
. 2019 Dec 5;44(Suppl 1):579–595. doi: 10.1038/s41386-019-0548-8